Newly activated UI Cancer Center clinical trials

Newly activated UI Cancer Center clinical trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on ClinicalTrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112.

E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Sponsor: Eastern Cooperative Oncology Group (ECOG-ACRIN Cancer Research Group)
Principal Investigator: Ardaman Shergill, MD
https://clinicaltrials.gov/ct2/show/NCT02201992?term=e4512&rank=2

MA.39: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Sponsor: Canadian Cancer Trials Group
Principal Investigator: Kent Hoskins, MD
NCT03488693, https://clinicaltrials.gov/ct2/show/NCT03488693?term=ma.39+tailor+rt&rank=1

EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
Sponsor: National Cancer Institute
Principal Investigator: Neeta Venepalli, MD
NCT03233711, https://clinicaltrials.gov/ct2/show/NCT03233711?term=ea2165&rank=1

A081105: Randomized Study of Erlotinib versus Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sponsor: National Cancer Institute
Principal Investigator: Ardaman Shergill, MD
NCT02193282, https://clinicaltrials.gov/ct2/show/NCT02193282?term=a081105&rank=2

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
This phase III ALCHEMIST trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.
Sponsor: National Cancer Institute
Principal Investigator: Ardaman Shergill, MD
NCT02595944, https://clinicaltrials.gov/ct2/show/NCT02595944?term=ea5142&rank=1

Leave a reply

Your email address will not be published. Required fields are marked *